As shown in Fig. 4a, Lipo-αCD137/Lipo-IL2-Fc combination therapy significantly delayed tumor outgrowth, while isotype control liposomes (Lipo-IgG) had no impact on tumor progression. Here, IL2 is linked to neoplasm.